公开(公告)号：WO2006088833A2

公开(公告)日：2006-08-24

申请号：PCT/US2006/005111

申请日：2006-02-14

Applicant: WYETH ,  CARRENO, Beatriz, M. ,  COLLINS, Mary ,  WRIGHT, Jill, F. ,  WOLFMAN, Neil, M. ,  ARAI, Maya ,  JACOBS, Kenneth ,  LU, Zhijian ,  GUO, Yongjing ,  QIU, Yongchang

Inventor： CARRENO, Beatriz, M. ,  COLLINS, Mary ,  WRIGHT, Jill, F. ,  WOLFMAN, Neil, M. ,  ARAI, Maya ,  JACOBS, Kenneth ,  LU, Zhijian ,  GUO, Yongjing ,  QIU, Yongchang

IPC: C07K16/24 ,  C07K16/28 ,  C07K14/54 ,  C07K14/715 ,  C12N15/11 ,  G01N33/68 ,  A61K39/39 ,  A61K39/395 ,  A61P37/00 ,  A61P29/00 ,  A61K38/20

CPC classification number: C07K16/244 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/55527 ,  C07K14/54 ,  C07K14/7155 ,  C07K16/2866 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/1138 ,  G01N33/6869

Abstract: The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling.

Abstract translation: 本发明提供与IL-17F信号通路相关的分离和纯化的多核苷酸和多肽。 本发明还提供了对IL-17F同源二聚体和IL-17A / IL-17F异二聚体的抗体，以及从天然来源分离和纯化IL-17家族成员（包括IL-17A / IL-17F异源二聚体）的方法。 本发明还涉及用于诊断，预后，监测与IL-17F信号传导相关的疾病的进展和/或预防的新方法，即IL-17F相关疾病，包括但不限于炎性 诸如自身免疫性疾病（例如关节炎（包括类风湿性关节炎），牛皮癣，系统性红斑狼疮和多发性硬化症），呼吸系统疾病（例如COPD，囊性纤维化，哮喘，过敏），移植排斥（包括实体器官移植排斥 ）和炎症性肠病或疾病（IBD，例如溃疡性结肠炎，克罗恩病）。 本发明还涉及新的治疗和治疗靶标，以及筛选和评估用于干预（治疗）的试验化合物和预防与IL-17F信号传导相关的紊乱的方法。

公开(公告)号：WO2006088833A3

公开(公告)日：2006-11-23

申请号：PCT/US2006005111

申请日：2006-02-14

Applicant: WYETH CORP ,  CARRENO BEATRIZ M ,  COLLINS MARY ,  WRIGHT JILL F ,  WOLFMAN NEIL M ,  ARAI MAYA ,  JACOBS KENNETH ,  LU ZHIJIAN ,  GUO YONGJING ,  QIU YONGCHANG

Inventor： CARRENO BEATRIZ M ,  COLLINS MARY ,  WRIGHT JILL F ,  WOLFMAN NEIL M ,  ARAI MAYA ,  JACOBS KENNETH ,  LU ZHIJIAN ,  GUO YONGJING ,  QIU YONGCHANG

IPC: C07K16/24 ,  A61K38/20 ,  A61K39/39 ,  A61K39/395 ,  A61P29/00 ,  A61P37/00 ,  C07K14/54 ,  C07K14/715 ,  C07K16/28 ,  C12N15/113 ,  G01N33/68

CPC classification number: C07K16/244 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/55527 ,  C07K14/54 ,  C07K14/7155 ,  C07K16/2866 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/1138 ,  G01N33/6869

Abstract: The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling.

Abstract translation: 本发明提供了与IL-17F信号传导途径相关的分离和纯化的多核苷酸和多肽。 本发明还提供针对IL-17F同二聚体和IL-17A / IL-17F异二聚体的抗体，以及从天然来源分离和纯化IL-17家族成员（包括IL-17A / IL-17F异二聚体）的方法。 本发明还涉及用于诊断，预测，监测IL-17F信号传导即IL-17F相关病症（包括但不限于炎症）的进展和治疗和/或预防与IL-17F信号传导相关的病症的新方法 （例如，关节炎（包括类风湿性关节炎），牛皮癣，系统性红斑狼疮和多发性硬化症），呼吸系统疾病（例如COPD，囊性纤维化，哮喘，变态反应），移植排斥（包括实体器官移植排斥 ）和炎性肠病或病症（IBD，例如溃疡性结肠炎，克罗恩氏病）。 本发明还涉及新的治疗剂和治疗靶，以及筛选和评估测试化合物用于干预（治疗）和预防与IL-17F信号传导相关的病症的方法。

公开(公告)号：WO2010039533A3

公开(公告)日：2010-04-08

申请号：PCT/US2009/058037

申请日：2009-09-23

Applicant: WYETH LLC ,  O'TOOLE, Margot ,  GUO, Yongjing ,  RAMSEY, Renee ,  BLOOM, Laird

Inventor： O'TOOLE, Margot ,  GUO, Yongjing ,  RAMSEY, Renee ,  BLOOM, Laird

IPC: A61K38/17 ,  A61K38/20 ,  C07K14/715 ,  C07K16/28

Abstract: The present invention provides human binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL21R), and uses therefore. The invention further provides methods to predict whether the binding proteins of the invention may take on agonistic activities in vivo and produce a cytokine storm. In addition, the invention provides methods for determining whether an anti-IL21R binding protein is a neutralizing anti-IL21R binding protein, based on the identification of several IL21-responsive genes. The binding proteins can act as, e.g., antagonists of IL21R activity, thereby modulating immune responses in general, and those mediated by IL21R in particular.

公开(公告)号：WO2010039533A2

公开(公告)日：2010-04-08

申请号：PCT/US2009058037

申请日：2009-09-23

Applicant: WYETH CORP ,  O'TOOLE MARGOT ,  GUO YONGJING ,  RAMSEY RENEE ,  BLOOM LAIRD

Inventor： O'TOOLE MARGOT ,  GUO YONGJING ,  RAMSEY RENEE ,  BLOOM LAIRD

IPC: A61K38/17 ,  A61K38/20 ,  C07K14/715 ,  C07K16/28

CPC classification number: G01N33/5041 ,  G01N33/5047 ,  G01N2333/54

Abstract: The present invention provides human binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL21R), and uses therefore. The invention further provides methods to predict whether the binding proteins of the invention may take on agonistic activities in vivo and produce a cytokine storm. In addition, the invention provides methods for determining whether an anti-IL21R binding protein is a neutralizing anti-IL21R binding protein, based on the identification of several IL21-responsive genes. The binding proteins can act as, e.g., antagonists of IL21R activity, thereby modulating immune responses in general, and those mediated by IL21R in particular.

Abstract translation: 本发明提供了特异性结合人白细胞介素-21受体（IL21R）的人结合蛋白及其抗原结合片段，并因此使用。 本发明进一步提供了预测本发明的结合蛋白是否可以在体内发挥激动活性并产生细胞因子风暴的方法。 另外，本发明提供了基于鉴定几种IL21应答基因来确定抗IL21R结合蛋白是否是中和性抗IL21R结合蛋白的方法。 结合蛋白可以充当例如IL21R活性的拮抗剂，从而通常调节免疫应答，特别是由IL21R介导的那些。